Vienna, 19 May 2022
Chemgineering International GmbH, an international ‘design & build’ partner for life science projects, is the EPCMV service provider for Maxicells ‘New blood plasma fractionation plant’ in Turkey. Maxicells, in collaboration with the Turkish Red Crescent, further aims to domestically produce plasma products from domestic blood plasma, and to consequently ensure that Turkey becomes a self-sufficient country in terms of producing
plasma products. Maxicells has set out to produce specific blood products that have already been manufactured by a few centers in the world, however not yet been produced in Turkey. Therefore, the design -as well as the construction have already been started to build the very first biological production facility for blood plasma
products in Turkey. The facility will produce 4 main plasma products (Immunoglobulin, Albumin, and the coagulation factors F-VIII and F-IX) as finished products in various sizes and concentrations. These drugs are used to treat e.g. hemophilia, certain infections, rheumatoid arthritis, leukemia and other immune system diseases, and will be made available nationwide for all patients in Turkey.
